Home | | | Search | | | Browse | | | Resources | | | Help | | | What's New | | | About |
---|
GM-CSF in Patients With Pulmonary Alveolar Proteinosis
This study is currently recruiting patients.
Sponsored by: | FDA Office of Orphan Products Development |
---|---|
Information provided by: | FDA Office of Orphan Products Development |
Purpose
This is a study to determine the efficacy and safety of granulocyte-macrophage colony-stimulating factor (GM-CSF, sargramostim) administered subcutaneously to patients with pulmonary alveolar proteinosis (PAP).
Condition | Treatment or Intervention | Phase |
---|---|---|
Pulmonary Alveolar Proteinosis |
Drug: GM-CSF (granulocyte-macrophage colony-stimulating factor, sargramostim) |
Phase II |
MedlinePlus related topics: Respiratory Diseases
Study Type: Interventional
Study Design: Treatment, Randomized, Placebo Control, Safety/Efficacy Study
Official Title: Trial of GM-CSF for Alveolar Proteinosis
Expected Total Enrollment: 48
Study start: September 2001;
Study completion: September 2004
PAP is a rare lung disease characterized by accumulation of surfactant phospholipids and proteins within the lungs. There is no specific pharmacologic therapy for PAP and the current practice of lung lavage under general anesthesia is invasive and has limitations. Although it is unknown if the anti GM-CSF antibody is related to the disease pathogenesis, observations suggest a role for GM-CSF in lung homeostasis as well as in the pathogenesis of PAP.
Patients will receive subcutaneous GM-CSF or placebo once a day and will be followed on an outpatient basis at 2 weeks, and 1, 2, 3, 4, 5 and 6 months after initiation of therapy. Clinical response will determine dosing schedule and will be evaluated by symptom scores, gas exchange data, and chest radiographs.
Eligibility
Ages Eligible for Study: 18 Years - 70 Years, Genders Eligible for Study: Both
Criteria
Inclusion criteria:
Exclusion criteria:
Location and Contact Information
More Information
U.S. National Library of Medicine, Contact NLM Customer Service | ||||||||||||||
National Institutes of Health, Department of Health & Human Services | ||||||||||||||
Copyright, Privacy, Accessibility, Freedom of Information Act |